 "pharmaceutical, pharma, testing, research, doctors, health, drugs, medicine, labaratory")
Shares of Jubilant Life Sciences, which scaled to a 52-week high on Wednesday, are up over 200 per cent since March lows.
Strong prospects in both pharmaceuticals and life sciences ingredients (LSI) segments — led by the specialty business, an agreement with Gilead Sciences for the domestic launch of remdesivir, recovering supplies of active ingredients, and others after easing of the lockdown, and a strong March quarter performance — have boosted sentiment. The company’s plan of demerging its pharmaceuticals and LSI segments could also lead to value unlocking for investors.
The launch of remdesivir — expected this month — remains the key
